Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,757,611
  • Shares Outstanding, K 119,918
  • Annual Sales, $ 26,680 K
  • Annual Income, $ -197,610 K
  • 60-Month Beta 2.00
  • Price/Sales 319.67
  • Price/Cash Flow N/A
  • Price/Book 9.92
Trade DNLI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.55
  • Number of Estimates 6
  • High Estimate -0.41
  • Low Estimate -0.67
  • Prior Year -0.56
  • Growth Rate Est. (year over year) +1.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.57 +17.67%
on 01/04/21
93.94 -19.12%
on 12/22/20
-9.62 (-11.24%)
since 12/18/20
3-Month
39.09 +94.37%
on 10/23/20
93.94 -19.12%
on 12/22/20
+33.42 (+78.52%)
since 10/19/20
52-Week
12.39 +513.24%
on 03/12/20
93.94 -19.12%
on 12/22/20
+53.62 (+239.80%)
since 01/17/20

Most Recent Stories

More News
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

DNLI : 75.98 (+4.04%)
Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

JPM : 138.04 (-0.43%)
DNLI : 75.98 (+4.04%)
5 Medical Outperformers That Might Lose Steam in 2021

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

MCRB : 24.96 (+1.96%)
NK : 18.34 (+6.32%)
CRSP : 198.29 (-0.80%)
RCKT : 53.63 (-2.58%)
DNLI : 75.98 (+4.04%)
Denali Therapeutics (DNLI) Surges: Stock Moves 5.7% Higher

Denali Therapeutics (DNLI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

ABEO : 2.14 (+12.04%)
DNLI : 75.98 (+4.04%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 8.20% and 57.60%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

DNLI : 75.98 (+4.04%)
Biogen and Denali to Collaborate on LRRK2 Program for Parkinson's Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

- Biogen to receive license to co-develop and co-commercialize Denali's small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson's disease and other movement disorders...

BIIB : 273.84 (-0.73%)
DNLI : 75.98 (+4.04%)
Dow Sheds Nearly 7% as Pullback Finally Arrives

Dow Sheds Nearly 7% as Pullback Finally Arrives

ZYXI : 18.05 (+9.26%)
TTD : 780.62 (-0.60%)
KMX : 116.43 (+9.39%)
KEY : 18.55 (+0.76%)
UNP : 215.28 (-0.61%)
R : 68.26 (+1.19%)
RCL : 73.48 (+0.77%)
TPC : 17.06 (+5.24%)
GSKY : 4.82 (-3.02%)
VECO : 20.81 (+4.42%)
DNLI : 75.98 (+4.04%)
What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock

Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DNLI : 75.98 (+4.04%)
Interesting DNLI Put And Call Options For December 18th

Investors in Denali Therapeutics Inc saw new options begin trading this week, for the December 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

DNLI : 75.98 (+4.04%)
Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates

Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 75.98 (+4.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO,...

See More

Key Turning Points

3rd Resistance Point 80.64
2nd Resistance Point 78.61
1st Resistance Point 77.30
Last Price 75.98
1st Support Level 73.95
2nd Support Level 71.92
3rd Support Level 70.61

See More

52-Week High 93.94
Last Price 75.98
Fibonacci 61.8% 62.79
Fibonacci 50% 53.17
Fibonacci 38.2% 43.54
52-Week Low 12.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar